Urinary System Diseases
Urinary system diseases encompass a wide range of conditions that affect the organs responsible for producing, storing, and eliminating urine. Rare urinary system diseases require more time and experience to study. Our company has long been committed to the construction of a drug and therapy development platform for rare urinary system diseases.
Overview of Urinary System Diseases
The urinary system, also known as the renal system, comprises the kidneys, ureters, bladder, and urethra. It plays a crucial role in maintaining fluid balance, eliminating waste products, and regulating blood pressure. Urinary system diseases encompass various conditions that disrupt the normal functioning of these organs. Among the less common urinary system diseases are focal segmental glomerulosclerosis (FSGS), primary hyperoxaluria (PH), lupus nephritis (LN), and membranous nephropathy (MGN).
Pathogenesis of Urinary System Diseases
Urinary system diseases can arise from diverse causes, encompassing infections, structural abnormalities, and genetic factors. Urinary tract infections typically occur when bacteria enter the urethra and subsequently spread to the bladder or kidneys. Kidney stones can form when specific substances in the urine crystallize and accumulate within the kidneys. Carcinogen exposure is often associated with urinary system cancer. Chronic kidney disease can develop as a result of conditions such as diabetes, high blood pressure, or certain autoimmune disorders.
Fig.1 Overview of the renal system and diseases. (Oroojalian, Fatemeh, et al., 2020)Therapeutic Strategies of Rare Urinary System Diseases
- Focal Segmental Glomerulosclerosis (FSGS): Dapagliflozin and Valsartan
- Immunoglobulin A Nephropathy (IgAN): Cyclophosphamide and Benzocaine
- Membranous Nephropathy (MGN): Mycophenolic acid and Clotrimazole
- Nephropathic Cystinosis (NC): Cysteamine and Sirolimus
- Polycystic Kidney Disease (PKD): Candesartan cilexetil and Angiotensin II
- Primary Hyperoxaluria (PH): Hydrochlorothiazide and Dapagliflozin
- Alport Syndrome (AS): Metformin and Hypoglycemic Agents
- Cystinuria (CSNU): Penicillamine and Antirheumatic Agents
- Renal Tubular Acidosis (RTA): Potassium citrate and Sodium citrate
Therapy Development for Urinary System Diseases
Small Molecule Drugs
Small molecule drugs play a crucial role in managing urinary system diseases. They can help control infections, reduce inflammation, manage pain, regulate blood pressure, and slow disease progression.
Regenerative Therapies
Regenerative medicine holds great promise for urinary system diseases. Stem cell therapy and tissue engineering approaches are being explored to regenerate damaged kidney tissue, restore bladder function, and repair urinary tract injuries.
Gene Therapies
Inherited genetic mutations can contribute to the development of urinary system diseases. Identifying and targeting these genetic aberrations can provide new avenues for therapy development.
Immune System Modulation
Modulating the immune response can be a promising approach for treating autoimmune-related urinary system diseases, such as certain forms of glomerulonephritis.
Our Services
At our company, we are proud to offer exceptional diagnostics and therapy development services for urinary system diseases. Our team of experts comprises highly skilled scientists and researchers with extensive experience in the field.
Rare Types of Urinary System Diseases
- Focal Segmental Glomerulosclerosis (FSGS)
- Immunoglobulin A Nephropathy (IgAN)
- Lupus Nephritis (LN)
- Membranous Nephropathy (MGN)
- Nephropathic Cystinosis (NC)
- Proliferative Lupus Nephritis (PLN)
- Polycystic Kidney Disease (PKD)
- Primary Hyperoxaluria (PH)
- Alport Syndrome (AS)
- Cystinuria (CSNU)
- Renal Tubular Acidosis (RTA)
Therapy Development Platforms
The rare disease model platform is another major feature of our company, which can model human urinary system diseases, including cell-based models, organoid models, and animal models. We also provide one-stop preclinical research services, such as drug safety evaluation and pharmacokinetic analysis.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Oroojalian, Fatemeh, et al. "Recent advances in nanotechnology-based drug delivery systems for the kidney." Journal of controlled release 321 (2020): 442-462.
- Dirks J, Remuzzi G, Horton S, et al. "Diseases of the Kidney and the Urinary System". Disease Control Priorities in Developing Countries. 2nd edition.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
